fosamprenavir (Lexiva)
Jump to navigation
Jump to search
Introduction
Tradename: Lexiva
Indications
Monitor
- lipid panel prior to initiating fosamprenavir & periodically thereafter[4]
Adverse effects
- nausea, diarrhea, rash[5]
- increases in serum cholesterol have occurred with treatment
- possible increased risk of myocardial infarction[2]
- drug adverse effects of antiretroviral protease inhibitors
- drug adverse effects of antiretroviral agents
Mechanism of action
- prodrug of amprenavir
More general terms
Additional terms
References
- ↑ Prescriber's Letter 11(2):suppl 2004
- ↑ 2.0 2.1 FDA MedWatch Lexiva (fosamprenavir calcium) - Dear Healthcare Professional Letter http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm192699.htm
- ↑ Department of Veterans Affairs, VA National Formulary
- ↑ 4.0 4.1 FDA Patient Safety News Cardiovascular Problems with Lexiva http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=95#2
- ↑ 5.0 5.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015